ILIAS BIOLOGICS INC
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
ILIAS Biologics Inc. demonstrated the therapeutic effect of anti-inflammatory exosomes for ischemia-reperfusion-induced acute kidney injury 2021-06-28 20:00
ILIAS Biologics announces the 2nd POC study, showing anti-inflammatory effects of ILB202 on preterm birth 2021-02-02 02:00
ILIAS Biologics Closes $20.6 Million Series B Financing 2020-09-28 19:00
ILIAS Biologics Granted Key Patent for Exosome-based Drug Delivery System in the United States 2020-07-08 01:00
1